Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells
- PMID: 16806496
- DOI: 10.1016/j.imlet.2006.05.001
Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells
Abstract
Mouse natural killer T cells with an invariant Valpha14-Jalpha18 TCR rearrangement (Valpha14i NKT cells) are able to regulate immune responses through rapid and large amounts of Th1 and Th2 cytokine production. It has been reported that in vivo administration of the Valpha14i NKT cell ligand, alpha-galactosylceramide (alpha-GalCer) significantly reduced morbidity and mortality of acute graft-versus-host disease (GVHD) in mice. In this study, we examined whether adoptive transfer of in vitro-expanded Valpha14i NKT cells using alpha-GalCer and IL-2 could modulate acute GVHD in the transplantation of spleen cells of C57BL/6 mice into (B6xDBA/2) F(1) mice. We found that the adoptive transfer of cultured spleen cells with a combination of alpha-GalCer and IL-2, which contained many Valpha14i NKT cells, modulated acute GVHD by exhibiting long-term mixed chimerism and reducing liver damage. Subsequently, the transfer of Valpha14i NKT cells purified from spleen cells cultured with alpha-GalCer and IL-2 also inhibited acute GVHD. This inhibition of acute GVHD by Valpha14i NKT cells was blocked by anti-IL-4 but not by anti-IFN-gamma monoclonal antibody. Therefore, the inhibition was dependent on IL-4 production by Valpha14i NKT cells. Our findings highlight the therapeutic potential of in vitro-expanded Valpha14i NKT cells for the prevention of acute GVHD after allogeneic hematopoietic stem cell transplantation.
Similar articles
-
Cytokine production and migration of in vitro-expanded NK1.1(-) invariant Valpha14 natural killer T (Valpha14i NKT) cells using alpha-galactosylceramide and IL-2.Immunol Lett. 2005 Nov 15;101(2):160-7. doi: 10.1016/j.imlet.2005.05.007. Immunol Lett. 2005. PMID: 16054231
-
Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.Immunology. 2005 Sep;116(1):30-7. doi: 10.1111/j.1365-2567.2005.02193.x. Immunology. 2005. PMID: 16108815 Free PMC article.
-
Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.Transfusion. 2010 Feb;50(2):407-17. doi: 10.1111/j.1537-2995.2009.02395.x. Epub 2009 Sep 24. Transfusion. 2010. PMID: 19788510
-
Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.Immunol Rev. 2007 Dec;220:183-98. doi: 10.1111/j.1600-065X.2007.00561.x. Immunol Rev. 2007. PMID: 17979847 Review.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2017 Jul 31;8:900. doi: 10.3389/fimmu.2017.00900. eCollection 2017. Front Immunol. 2017. PMID: 28824628 Free PMC article. Review.
-
Pre-transplant donor CD4- invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease.Leukemia. 2017 Apr;31(4):903-912. doi: 10.1038/leu.2016.281. Epub 2016 Oct 14. Leukemia. 2017. PMID: 27740636
-
Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.Cytotherapy. 2020 May;22(5):276-290. doi: 10.1016/j.jcyt.2020.01.011. Epub 2020 Mar 29. Cytotherapy. 2020. PMID: 32238299 Free PMC article.
-
Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease.Front Immunol. 2022 Nov 17;13:1045168. doi: 10.3389/fimmu.2022.1045168. eCollection 2022. Front Immunol. 2022. PMID: 36466922 Free PMC article. Review.
-
Human CD4- invariant NKT lymphocytes regulate graft versus host disease.Oncoimmunology. 2018 Aug 23;7(11):e1470735. doi: 10.1080/2162402X.2018.1470735. eCollection 2018. Oncoimmunology. 2018. PMID: 30377560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources